Ashling Wahner

Andrew W. Hahn, MD, discusses the efficacy and safety of lenvatinib plus everolimus in metastatic ccRCC after progression on PD-1–directed ICIs

Jessica C. Hassel, MD, discusses the mechanism of action of the IO102-IO103 vaccine and the implications of its efficacy data in melanoma.

A target action date of August 30, 2026, has been set for the FDA's decision regarding the sBLA seeking the approval of ropeginterferon alfa-2b for ET.

Patients with relapsed/refractory MCL had poor treatment outcomes with BTK inhibition, which decreased in quality as the line of therapy advanced.

Nivolumab plus ipilimumab continued to yield an efficacy and safety benefit vs lenvatinib or sorafenib in previously untreated, unresectable HCC.

Brian Slomovitz, MD, discusses key trials and surgical advances for patients with ovarian cancer.

Zolbetuximab plus chemotherapy delivered maximal clinical benefits when AEs were managed effectively in CLDN18.2-positive advanced gastric/GEJ cancer.

Zolbetuximab plus mFOLFOX6 and nivolumab was effective and tolerable across biomarker-defined subgroups in unresectable gastric/GEJ adenocarcinoma.

The FDA has received a new drug application seeking the approval of rusfertide for the treatment of adult patients with polycythemia vera.

Jason Mouabbi, MD, discusses the emerging role of ctDNA tests in breast cancer management and their use in early detection and treatment monitoring.

The FDA has received a new drug application seeking the approval of bezuclastinib for the treatment of patients with non-advanced systemic mastocytosis.

In case you missed any, read a recap of every episode of OncLive On Air that aired in December 2025.

Primo Nery “Lucky” Lara Jr, MD, has built a genitourinary oncology career inspired by optimism, rooted in perseverance, expanded by innovative thinking, and strengthened by a belief in the power of team science.

Post-neoadjuvant T-DXd has received breakthrough therapy designation from the FDA for HER2-positive early breast cancer with residual invasive disease.

The NMPA has accepted a new drug application for tinengotinib tablets for the treatment of patients with pretreated advanced/metastatic cholangiocarcinoma.

The subcutaneous formulation of amivantamab has received FDA approval for refractory, EGFR-mutant non–small cell lung cancer.

Hematology experts share the AML and ALL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.

IGV-001 produced an OS benefit vs placebo in newly diagnosed glioblastoma.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

Pembrolizumab obtained approval from the European Commission for subcutaneous administration for all adult indications.

IsoPSA has been FDA approved for use as an aid in the diagnosis of high-grade prostate cancer in men at least 50 years of age with elevated PSA levels.

Sonrotoclax is under priority review by the FDA for the treatment of adult patients with relapsed or refractory, BTK inhibitor–pretreated MCL.

Christine Ryan, MD, discusses the limitations of current MCL treatment strategies, advances in treatment, and the evolving role of BTK inhibition.

In a recent Peer Exchange, bladder cancer experts reviewed the current treatment paradigm for muscle-invasive bladder cancer (MIBC) and discussed updates from ESMO 2025.

18F-Fluciclovine PET/MRI detected disease progression and ruled out disease in non-progressors among patients with solid tumor brain metastases.

Erdafitinib had a safety profile that was deemed tolerable in patients with recurrent or progressive IDH wild-type glioma harboring F3T3 gene fusions.

Temozolomide plus radiotherapy significantly improved OS vs radiotherapy alone in IDH-mutant low-grade gliomas without codeletions of 1q and 19q.

B7-H3–directed CAR T-cell therapy given intraventricularly was well tolerated and showed early efficacy signals in patients with recurrent glioblastoma.

Mirdametinib had clinical activity and was deemed well tolerated in MEK inhibitor–naive pediatric patients with recurrent/progressive low-grade glioma.

The FDA approved epcoritamab plus rituximab and lenalidomide for relapsed or refractory follicular lymphoma indications.